) recently jumped 6.30% on potential buyout rumors.
As per Reuters, several pharmaceutical companies have shown an
interest in acquiring ViroPharma given the company's orphan
disease drug portfolio.
The company's key drugs include Cinryze for hereditary
angioedema (HAE), Plenadren for the treatment of adrenal
insufficiency (AI), Buccolam in Europe for the treatment of
pediatric seizures, and Vancocin for the treatment of C.
difficile- associated diarrhea (CDAD).
We note that ViroPharma's growth story currently revolves
around Cinryze, which is approved in the US for routine
prophylaxis against angioedema attacks in adolescent and adult
patients with HAE. Cinryze accounted for 76% of total sales in
In the EU, Cinryze received approval for routine prevention,
pre-procedure prevention and acute treatment of angioedema
attacks in adults and adolescents in 2011.
Cinrzye has been granted marketing exclusivity by the FDA
until 2015 under the Orphan Drug Act.
ViroPharma has begun commercializing Buccolam in Europe paving
the way for an additional revenue opportunity.
Additionally, the acquisition of Plenadren in 2011 expanded
the company's orphan disease commercial product portfolio
although the approval process for Plenadren hit a roadblock when
the FDA informed the company that the data filed by it in the EU
regarding Plenadren was not sufficient for evaluating the
risk/benefit profile of the drug in the US.
Meanwhile, an interesting candidate in ViroPharma's pipeline
is maribavir which is being developed for the treatment of
cytomegalovirus (CMV) infections in transplant recipients.
ViroPharma recently received 'orphan drug designation' in the
EU for maribavir for the treatment of CMV in patients suffering
from impaired cell mediated immunity.
Maribavir was granted the same designation in the US in May
2011 for the treatment of clinically significant CMV and disease
in at-risk patients.
We expect investor focus to remain on takeover updates. Shares
have gone up 5.4% on a year-to-date basis and we expect further
increase if the buyout rumors gather momentum.
ViroPharma currently carries a Zacks Rank #3 (Hold). Right
) look attractive with a Zacks Rank #1 (Strong Buy).
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
VIROPHARMA (VPHM): Free Stock Analysis Report
To read this article on Zacks.com click here.